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NEOPLASIA
Leukemia-associated NF1 inactivation in patients with pediatric T-ALL and AML
lacking evidence for neurofibromatosis
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Neurofibromatosis type 1 (NF1) is an auto-
somal dominant genetic disorder caused
by mutations in the NF1 gene. Patients
with NF1 have a higher risk to develop
juvenile myelomonocytic leukemia (JMML)
with a possible progression toward acute
myeloid leukemia (AML). In an oligo array
comparative genomic hybridization–based
screening of 103 patients with pediatric T-
cell acute lymphoblastic leukemia (T-ALL)
and 71 patients with MLL-rearranged AML, a
recurrentcrypticdeletion,del(17)(q11.2),was
identified in 3 patients with T-ALL and 2
patients with MLL-rearranged AML. This de-
letion has previously been described as a
microdeletion of the NF1 region in patients
with NF1. However, our patients lacked clini-
cal NF1 symptoms. Mutation analysis in 4 of
these del(17)(q11.2)-positive patients re-
vealed that mutations in the remaining NF1
allele were present in 3 patients, confirming
its role as a tumor-suppressor gene in can-
cer. In addition, NF1 inactivation was con-
firmed at the RNA expression level in 3
patients tested. Since the NF1 protein is a
negative regulator of the RAS pathway (RAS-
GTPase activating protein), homozygous
NF1 inactivation represent a novel type I
mutation in pediatric MLL-rearranged AML
and T-ALL with a predicted frequency that is
less than 10%. NF1 inactivation may provide
an additional proliferative signal toward the
development of leukemia. (Blood. 2008;111:
4322-4328)
© 2008 by The American Society of Hematology
Introduction
Neurofibromatosis type 1 (NF1) is an autosomal genetic disorder
that is clinically characterized by cafe-au-lait spots and frequent
fibromatous tumors of the skin and tumors of the central nervous
system. The NF1 disorder is caused by genetic heterozygous
mutations in the NF1 gene on chromosome 17q11.2. Most NF1
mutations are intragenic and have been found over the complete
gene. They comprise a diversity of mutation types, where splicing
mutations are particularly prevalent given the number of exons.
This results in truncation for a large percentage of patients, thereby
inactivating the encoded protein neurofibromin.1 Another genetic
aberration includes microdeletions affecting the entire NF1 locus.
Patients with these NF1 microdeletions display a more severe NF1
phenotype, characterized by mental retardation, facial dysmor-
phism, and increased risk for developing malignant tumors,
including leukemias.2,3 To this end, NF1 has also been associated
with juvenile myelomonocytic leukemia (JMML), with a risk of
progression toward acute myeloid leukemia (AML). These malig-
nancies are associated with loss of the wild-type allele, either
through deletions or the acquisition of point mutations. In JMML, it
has also frequently been reported that the wild-type allele is
replaced by the mutant allele as an effect of recombinational events
leading to uniparental disomy (UPD).4-6 Previously, it was shown
that biallelic inactivation of NF1 are found as somatic abnormali-
ties in patients with JMML who lack clinical evidence of NF1.7
Somatic inactivation of Nf1 in hematopoietic cells results in a
progressive myeloproliferative disorder in mice,8 confirming that
NF1 acts as a tumor-suppressor gene.5 The NF1 gene protein
product, neurofibromin, is a GTPase-activating protein (GAP) that
inhibits RAS signaling by hydrolysis of active RAS-GTP into
inactive RAS-GDP.1,9 Therefore, NF1 deficiencies act as functional
equivalents of activational mutations in RAS. Indeed, NF1 inactiva-
tion and RAS mutations have been found in a mutually exclusive
manner in JMML.7
AML is a heterogeneous disease in which early treatment
response and cytogenetic abnormalities are the most important
prognostic factors. In AML, genetic aberrations can be classified as
type I or type II mutations. One hypothesis about the development
of AML is the coexistence of both type I and type II mutations that
confer proliferative signals (type I mutations affecting the FLT3,
C-KIT, NRAS, KRAS, or PTPN11 genes) in combination with type
II differentiation-impairing mutations (such as PML-RAR, AML-
ETO, CBFB-MYH11, or MLL-rearrangements).10
MLL-rearrangements account for 8% to 20% of all cytogenetic
abnormalities in pediatric AML.11,12 HOX genes are the prime
targets of MLL fusion products and regulate cellular differentiation
in normal hematopoietic development. However, Eguchi et al point
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to another role of MLL fusion products in MLL-rearranged
leukemias through the alteration of cell-cycle arrest and apopto-
sis.13 Most of these MLL-positive AML samples are morphologi-
cally classified as FAB-M4 and FAB-M5, and it has been suggested
that MLL-rearrangements in pediatric AML are associated with a
poor outcome. Interestingly, in some studies the t(9;11) subgroup
has been associated with a higher sensitivity to different classes of
drugs and a better prognosis.14-16 In addition, many of these patients
with MLL-rearranged AML lack mutations in FLT3, C-KIT, NRAS,
KRAS, and PTPN11, indicating that the type I mutations remains to
be elucidated. High-resolution genomic screening of patients with
MLL-rearranged AML could provide us with further insight into
novel genetic aberrations with prognostic significance or new type
I mutations in MLL-rearranged AML.
T-cell acute lymphoblastic leukemia (T-ALL) represents about
15% of patients with pediatric ALL and is characterized by a rapid
progression of disease and a 30% relapse rate within the first
2 years after diagnosis.17 In the last decade, a large number of new
Figure 1. NF1 microdeletions in pediatric acute leukemias. (A) Chromosome 17 ideogram and corresponding oligo array-CGH plot of patient DNA/control DNA ratios (blue
tracing) versus the dye-swap experiment (red tracing) for T-ALL patient no. 2736. (B) Detailed visualization of the NF1 microdeletion at chromosomal band 17q11 in T-ALL
patient no. 2736. Hybridization signals around the2X or2X lines represent loss of the corresponding region in the patient DNA. (C) Detailed analysis of the centromeric (left
panel) and telomeric (right panel) breakpoint of the NF1 microdeletion in patient no. 2736. (D) Overview of oligo array-CGH results in the chromosomal region 17q11.2 for
3 patients with T-ALL and 2 patients with AML with del(17)(q11.2). The 60-mer oligos present on the DNA array and located in this genomic area, as well as the specific genes
located in this region with their transcription direction, are shown. Arrows above the indicated genes represent the direction of transcription. N indicates normal; L, loss; cen,
centromere; and tel, telomere.
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genomic aberrations were identified in T-ALL, including chromo-
somal translocations, deletions, amplifications, and mutations.18-20
All these genetic defects target different cellular processes, includ-
ing the cell cycle, T-cell differentiation, proliferation, and survival.
Cooperation of these genetic events initiates leukemic transforma-
tion of thymocytes.18 RAS mutations have been found in less than
5% of patients with T-ALL, showing that proliferative hits
affecting the RAS pathway remain rare.18 On the other hand, more
than 50% of the patients with T-ALL are characterized by
activating mutations in the NOTCH1 pathway, including the
NOTCH1 gene itself21,22 or the NOTCH1-regulating U3-ubiquitin
ligase FBXW7.23,24
In this study, we used oligo array–comparative genomic hybrid-
ization (array-CGH) and identified somatic NF1 microdeletions as
a cryptic genetic abnormality in patients with pediatric T-ALL and
patients with MLL-rearranged AML that lack symptoms of neurofi-
bromatosis. We present further evidence for the role of NF1
inactivation as a functional equivalent to activated RAS signaling,
and suggest that this can be considered as a new type I mutation in
MLL rearranged AML and a proliferative hit in T-ALL.
Methods
Patients
Viably frozen diagnostic bone marrow or peripheral blood samples from
103 patients with pediatric T-ALL and 71 patients with pediatric MLL-
rearranged AML were provided by the Dutch Childhood Oncology Group
(DCOG), the German Cooperative Study Group for Childhood Acute
Lymphoblastic Leukemia (COALL), and the Berlin-Frankfurt-Mu¨nster
AML Study Group (AML-BFM-SG). Informed consent was obtained
according to local law and regulations and in accordance with the
Declaration of Helsinki. Leukemic cells were isolated and enriched from
these samples as previously described.25 All resulting samples contained
90% or more leukemic cells, as determined morphologically by May-
Gru¨nwald-Giemsa (Merck, Darmstadt, Germany)–stained cytospins. These
leukemic cells were used for DNA and RNA extraction, and a minimum of
5  106 leukemic cells were lysed in Trizol reagent (Gibco BRL/Life
Technologies, Breda, The Netherlands) and stored at 80°C. Genomic
DNA and total cellular RNA were isolated as described before.25 From the
patients with a deletion of NF1, remission and relapse material was only
available for patient no. 2736.
Oligo array-CGH
Oligo array-CGH analysis was performed on the human genome CGH
Microarray 44k-A (Agilent Technologies, Palo Alto, CA) according to the
manufacturer’s protocol using a dye-swap experimental design to minimize
false positive results, as previously described.25,26
MLPA
Multiplex ligation-dependent probe amplification (MLPA) analysis was
performed using the SALSA P081/082 MLPA assay (MRC Holland,
Amsterdam, the Netherlands). SALSA P081/082 consists of 2 reaction
mixes containing probes for all constitutive NF1 exons except for exons
5, 7, 17, 19A, 45, and 47. The exact localization of the MLPA probes can
be downloaded from the MRC Holland website (http://www.mrc-
holland.com/pages/p081 p082pag.html). The 2 reactions contain
15 and 13 control probes in other regions of the genome, respectively.
The patients’ samples were analyzed with MLPA according to the
manufacturer’s protocol.27,28 Data were analyzed using GeneMarker
v1.5 (Softgenetics, State College, PA).
Mutation analysis
For the detection of NF1 mutations, DNA was subjected to 40 cycles of
polymerase chain reaction (PCR) of 15 minutes at 95°C and 1 minute at Ta
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60°C, using specific primers for all NF1 exons, which are being used in
NF1 diagnostics (Department of Clinical Genetics, Erasmus MC,
Rotterdam, The Netherlands, A.M.W.O. manuscript in preparation;
primers are available on request at a.vandenouweland@erasmusmc.nl).
RAS, PTPN11 and C-KIT mutation screening was performed as de-
scribed in Table S1, available on the Blood website (see the Supplemen-
tal Materials link at the top of the online article). NOTCH1 and FLT3
mutational screening were done as previously described.21,29,30 PCR
products were purified by standard methods and directly sequenced from
both strands. The sequence data were analyzed using Seqscape V2.5
(Applied Biosystems, Foster City, CA).
NF1 expression analysis
NF1 expression was calculated based upon nonnormalized gene expression
array data, performed on the human genome U133 Plus 2.0 array
(Affymetrix, Santa Clara, CA) as previously described,31 which were
available for 3 del(17)(q11.2)-positive and 7 del(17)(q11.2)-negative leuke-
mia patients. For the NF1 probe sets, the expression was normalized to the
median expression of GAPDH (6 probesets) for each patient sample. The
difference in relative gene expression levels between patients with and
without the del(17)(q11.2) was evaluated using the Mann-Whitney U test.
Results
High-resolution genomic screening of a selected subgroup of
103 patients with pediatric T-ALL and 71 patients with MLL-
rearranged AML using a 44K oligo array-CGH platform led to the
identification of a cryptic deletion, del(17)(q11.2). This deletion
was recurrently observed in 3 patients with T-ALL and 2 patients
with AML (Figure 1A,B; Table 1). These deletions were about
1.2 Mb in size and covered the NF1 gene. For all patients, the
telomeric breakpoints were situated in the JJAZ1 gene, whereas the
centromeric breakpoints clustered in its pseudogene JJAZ1P (Fig-
ure 1C,D). The deletion area in these samples was equivalent to
those observed in patients with NF1. Genetic and clinical patient
characteristics for all del(17)(q11.2)-positive leukemia patients are
summarized in Table 1. One of the 3 patients with T-ALL and at
least one of the 2 patients with AML relapsed.
To further confirm the deletion breakpoints, 4 of 5 del(17)(q11.2)-
positive leukemia patients and 15 del(17)(q11.2)-negative controls
(7 with T-ALL and 8 with AML) were analyzed using an NF1
locus–specific MLPA assay.27,28 No residual material was available
for patient no. 6421. These analyses confirmed that one copy of the
NF1 locus was lost in all 4 of these patients (Figure 2; only T-ALL
patient no. 2736 is shown), whereas all control patients retained
both copies of the NF1 gene (only AML control no. 3339 is shown).
In order to investigate complete NF1 inactivation in our
patients, we performed mutation analysis on all exons and exon/
intron boundaries of the NF1 gene in the 4 del(17)(q11.2)-positive
patients with leukemia, and in an additional group of 39 patients
without a deletion involving chromosomal band 17q11.2 (including
21 patients with MLL-rearranged AML and 18 patients with
T-ALL). Small frameshift mutations disrupting the NF1 coding
region were only detected in 3 of 4 del(17)(q11.2)-positive patients
(Table 1; Figure 3), leading to biallelic inactivation of NF1 in these
patients. One patient with T-ALL and 2 patients with MLL-
rearranged AML without a del(17)(q11.2) had a monoallelic
mutation in nonfunctional domains, possibly reflecting rare poly-
morphisms. Furthermore, NF1 expression in the del(17)(q11.2)-
positive patients with T-ALL and MLL-rearranged AML leukemias
was significantly lower in 3 patients tested, as compared
with 7 T-ALL and AML patient samples that are wild-type for
NF1 (Figure 4).
To further verify a somatic rather than a genetic origin of
NF1 inactivation, we screened relapse and remission material of
T-ALL patient no. 2736, for whom material was available. At
relapse, the NF1 microdeletion and NF1 mutation on the other
allele were present, while in the remission sample both muta-
tions remained undetected.
Since NF1 deficiency could act as a novel type I mutation, we
screened all del(17)(q11.2)-positive patients with leukemia for
activational mutations in RAS. Although NRAS or KRAS mutations
have been described in MLL-rearranged AML and T-ALL, no
somatic NRAS or KRAS mutations were found in our
5 del(17)(q11.2)-positive patients with leukemia. In addition, both
patients with MLL-rearranged AML with a NF1 deletion lacked
other type I mutations in FLT3, C-KIT, or PTPN11 in their
leukemic cells. The frequency of these mutations in the
71 MLL-rearranged AML samples was low, as expected. Only 35%
had one of these mutations, and all these mutations were mutually
exclusive. Furthermore, the del(17)(q11.2)-positive patients with
T-ALL were screened for rearrangements at the TAL1, HOX11L2,
HOX11, CALM-AF10, MLL and cMYC loci or the presence of
NOTCH1 mutations. One patient (no. 167) lacked rearrangements
of any of the loci mentioned above, whereas a HOX11L2 transloca-
tion (no. 2780) and a CALM-AF10 fusion gene (no. 2736) were
detected in 2 other patients. NOTCH1 mutations were identified in
Figure 2. MLPA analysis of NF1 in selected cases.
MLPA analysis of the NF1 locus in T-ALL patient no. 2736
and AML patient no. 3339. Normalized peak areas
around 0.5 represent monoallelic loss of the correspond-
ing genomic region.
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patients no. 2780 (heterodimerization domain; L1601P) and no.
167 (PEST domain; 2445insLL).
Discussion
Genetic events that lead to leukemogenesis by activating uncon-
trolled cell proliferation remain to be elucidated in most patients
with pediatric T-ALL and MLL-rearranged AML. We used oligo
array-CGH to identify new abnormalities and found somatic NF1
microdeletions as a cryptic genetic abnormality in patients lacking
clinical symptoms of neurofibromatosis. This array-CGH study is
currently expanded to other subtypes of leukemias. Recent single
nucleotide polymorphism (SNP) array analysis of pediatric ALL by
investigators from St Jude Children’s Research Hospital showed
that this microdeletion in NF1 may be present at low frequencies in
other types of acute leukemia as well.32
NF1 microdeletions are observed in about 5% to 20% of
patients with NF1.1 The majority of these patients with NF1 have a
1.4-Mb NF1 microdeletion due to interchromosomal homologous
recombination between the low-copy repeats of the WI-12393 gene
flanking NF1 and sequences with homology to chromosome
19 during meiosis.33 A second type of NF1 microdeletions of about
1.2 Mb in size is due to a mitotic intrachromosomal recombination
between the JJAZ1 and the homologous JJAZ1P pseudogene.34,35
The NF1 microdeletions in our leukemia patients seemed identical
to this 1.2 Mb microdeletion type.33 However, in contrast to
patients with NF1 with similar NF1 deletions, our patients with
leukemia did not meet the clinical criteria for NF1, lacking
cafe-au-lait spots, mental retardation, and/or facial dysmor-
phism. This suggests that the NF1 deletion in our patients is
somatic and leukemia specific, rather than of constitutional
genetic origin, although molecular diagnostics for NF1 was not
performed in these patients.
Deletion of one allele of NF1 and further inactivation of the
other NF1 allele in 3 patients through the acquisition of point
mutations further confirms the role of NF1 as a tumor-suppressor
gene in the pathogenesis of both pediatric MLL-rearranged AML
and T-ALL. This point was further strengthened by the finding of
clonal stability in one of the del(17)(q11.2) patients, where the
deletion of NF1 on one allele and the point mutation in the other
NF1 allele were both present at diagnosis and relapse while absent
in the remission sample. Therefore, the NF1 abnormalities were of
somatic origin in at least patient no. 2736 and were only present in
the leukemic cells. Similar findings have been described for
patients with JMML,7 explaining why these patients did not have
any clinical symptoms of neurofibromatosis.
Since NF1 deficiency leads to the activation of the RAS
signaling pathway,9 and none of the del(17)-positive patients
with leukemia had mutations in NRAS or KRAS, NF1 microdele-
tions presumably provide an alternative mechanism for RAS
activation in both MLL-rearranged myeloid and T-lymphoid
Figure 3. Truncating NF1 mutations in pediatric T-ALL and AML. (A) Sequence
analysis of patient no. 4389 (AML) showing a c.2849_2850insTT mutation in the
remaining NF1 allele. (B) Sequence analysis of patient no. 2736 (T-ALL) showing a
c.3734delCinsGGTTTATGGTTT mutation in the remaining NF1 allele. (C) Sequence
analysis of patient no. 2780 (T-ALL) showing a c.333dupA mutation in the remaining
NF1 allele.
Figure 4. NF1 expression analysis in pediatric T-ALL and MLL-rearranged AML.
NF1 mRNA expression data relative to GAPDH (%), based upon gene expression
array data, which were available for 3 del(17)(q11.2)-positive (patient no. 2736, 2780,
and 167) and 7 del(17)(q11.2)-negative patients with leukemia. The horizontal bars
represent median relative expression.
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leukemias, thereby representing a novel type I abnormality.
These patients with leukemia may potentially benefit from
additional treatment with RAS inhibitors like farnesylthiosali-
cylic acid36 or downstream inhibitors.
Both del(17)-positive patients with AML were further screened
for any of the other currently known type I mutations in AML. As
expected, no other type I mutations were detected, indicating that
NF1 microdeletions could act as a novel type I mutation which
cooperate with the MLL translocation (type II mutation) in the
pathogenesis of AML.
The idea of a multistep pathogenesis in T-cell leukemia is
widely accepted.18-20,37 Cooperative genetic events affect cell cycle,
T-cell differentiation, proliferation, and survival. We identified a
number of cooperative aberrations in the del(17)(p11.2)-positive
T-ALL samples. NOTCH1 mutations, generally present in about
50% of T-ALL,21 were identified in 2 of 3 del(17)(p11.2)-positive
T-ALL samples. In addition, genetic aberrations that induce a T-cell
differentiation arrest were identified in patient no. 2780 (HOX11L2
translocation) and patient no. 2736 (CALM-AF10 translocation).
These data further suggests that loss of NF1 can be involved in the
development of T-ALL, as one of the genetic hits in multistep
oncogenesis.
In this study, we identified 3 patients whith a deletion of NF1
and an inactivational mutation on the remaining allele. We could
not identify homozygous somatic NF1 mutations in 21 patients
with MLL-rearranged AML and 18 patients with T-ALL without a
microdeletion. This suggests that the frequency of biallelic inactiva-
tion, until now the only mechanism described for oncogenesis, is
less than 10% in these groups.
Other mechanisms of NF1 inactivation, such as inactivation
through the duplication of the mutated (UPD) NF1 allele at the
expense of the remaining wild-type allele, as observed in patients
with NF1 with JMML, may have been missed.6 Of interest, recent
SNP array analysis of pediatric ALL, and JMML without underly-
ing NF1, showed that there was no UPD involved in the NF1
region.6,32 In addition, in adult AML approximately 20% have large
regions of UPD, but none of them involves the NF1 locus.38,39
Hence, UPD of the NF1 locus may be a rare event in leukemias of
somatic origin compared with leukemias which originate from
patients with clinical evidence of NF1. Therefore, the frequency of
biallelic NF1 inactivation in pediatric MLL-rearranged AML and
T-ALL as we reported here may be underestimated. Future studies
should be extended by sequencing the NF1 locus, including the
promoter region and the 3 untranslated region (UTR), and look for
abnormalities in NF1 protein expression.
In conclusion, we report the identification of NF1 microdele-
tions in patients with pediatric T-ALL and MLL-rearranged AML
without clinical evidence of NF1. We confirmed NF1 inactivation
by reduced NF1 expression levels and biallelic NF1 mutations in
3 of 5 patients, confirming the role of NF1 as a tumor-suppressor
gene in cancer. NF1 inactivation is a novel type I mutation in
MLL-rearranged AML and a new proliferative hit in T-ALL.
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